可溶性白细胞介素-2受体在恶性血液病中的表达及意义

被引：5

作者：

张丽娟

仇红霞

机构：

[1] 南京医科大学第一附属医院血液科

来源：

国际输血及血液学杂志 | 2010年 / 05期

关键词：

血清; 可溶性白细胞介素-2受体; 免疫功能; 肿瘤负荷;

D O I：

暂无

中图分类号：

R733 [造血器及淋巴系肿瘤];

学科分类号：

100214 ;

摘要：

可溶性白细胞介素-2受体(sCD25)作为一种可溶性的细胞因子受体广泛分布于人体液中。正常人体内可少量表达,主要来源于激活的淋巴细胞。机体病态时,过多活化的淋巴细胞或肿瘤细胞大量释放sCD25。研究表明,在多种疾病的发展过程中,如恶性肿瘤、自身免疫性疾病、感染性疾病、某些传染病及器官移植排斥反应等,均可见血清sCD25水平增高,并且与疾病的进展及预后有较大的关系。本文就sCD25在恶性血液病中的表达及意义作一综述。

引用

页码：453 / 455

共 12 条

[1] NK细胞活性与血清可溶性CD25水平检测在继发性噬血细胞性淋巴组织细胞增多症诊断中的意义 [J].

王昭 ;

王旖旎 ;

冯翠翠 ;

田莉萍 ;

陈皙 .

中国实验血液学杂志, 2008, (05) :1154-1157

[2]

Soluble immune receptor serum levels are associated with age, but not with clinical phenotype or disease severity in childhood atopic dermatitis[J] . Journal of the European Academy of Dermatology and Venereology . 2010 (4)

[3] Serum soluble interleukin-2 receptor levels in patients with malignant lymphoma of bone [J].

Akahane, Tsutomu ;

Shimizu, Tominaga ;

Isobe, Ken'ichi ;

Yoshimura, Yasuo ;

Kato, Hiroyuki .

JOURNAL OF ORTHOPAEDIC SCIENCE, 2009, 14 (03) :248-252

[4]

Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin’s lymphoma: comparison with serum soluble interleukin-2 receptor values[J] . Mitsuaki Tatsumi,Hiroyuki Sugahara,Ichiro Higuchi,Hiroki Fukunaga,Hironobu Nakamura,Yuzuru Kanakura,Jun Hatazawa.International Journal of Clinical Oncology . 2009 (2)

[5]

Serum soluble interleukin 2 receptor &agr;in human cancer of adults and children: a review[J] . E. Bien,A. Balcerska.Biomarkers . 2008 (1)

[6] Clinical significance of the serum IL-2R level and Ga-67 scan findings in making a differential diagnosis between sarcoidosis and non-Hodgkin's lymphoma [J].

Kita, Tamotsu ;

Watanabe, Sadahiro ;

Yano, Fuzuki ;

Hayashi, Katsumi ;

Yamamoto, Masayoshi ;

Iwasaki, Yoshie ;

Kosuda, Shigeru .

ANNALS OF NUCLEAR MEDICINE, 2007, 21 (09) :499-503

[7] Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma [J].

Kuku, I ;

Bayraktar, MR ;

Kaya, E ;

Erkurt, MA ;

Bayraktar, N ;

Cikim, K ;

Aydogdu, I .

MEDIATORS OF INFLAMMATION, 2005, (03) :171-174

[8] A case of Vogt-Koyanagi-Harada disease associated with malignant lymphoma [J].

Hashida, N ;

Kanayama, S ;

Kawasaki, A ;

Ogawa, K .

JAPANESE JOURNAL OF OPHTHALMOLOGY, 2005, 49 (03) :253-256

[9]

Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival[J] . Philipp Schütt,Peter Ebeling,Ulrike Buttkereit,Dieter Brandhorst,Bertram Opalka,Miriam Poser,Siemke Müller,Michael Flasshove,Thomas Moritz,Siegfried Seeber,Mohammad Resa Nowrousian.Annals of Hematology . 2005 (9)

[10]

Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index[J] . Hideko Goto,Hisashi Tsurumi,Masao Takemura,Yoriko Ino-Shimomura,Senji Kasahara,Michio Sawada,Toshiki Yamada,Takeshi Hara,Kenji Fukuno,Naoe Goto,Masataka Okuno,Tsuyoshi Takami,Mitsuru Seishima,Hisataka Moriwaki.Journal of Cancer Research and Clinical Oncology . 2005 (2)

← 1 2 →